Manuel Aivado has been appointed president and CEO of Aileron Therapeutics (NASDAQ: ALRN). He has also been elected to the Watertown, MA-based company’s board of directors. Aivado, who was Aileron’s chief medical and scientific officer, joined the company in 2014. Aileron started looking for a new CEO in May, after Joseph Yanchik suddenly resigned after 12 years at the company. Aileron’s lead drug, ALRN-6924, is being tested in multiple clinical trials as a treatment for various cancers.